Stecher S-S, Stemmler H J, Tischer J, von Bergwelt-Baildon M, Liebregts T, Fraccaroli A
Medizinische Klinik und Poliklinik II, Gastroenterologie & Hepatologie, Klinikum der Ludwig-Maximilians-Universität München, München, Deutschland.
Medizinische Klinik und Poliklinik III, Hämatologie und Onkologie, Klinikum der Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, München, Deutschland.
Med Klin Intensivmed Notfmed. 2021 Mar;116(2):111-120. doi: 10.1007/s00063-021-00782-8. Epub 2021 Feb 9.
Allogeneic hematopoetic stem cell transplantation yields improved long-term survival for patients with high-risk malignant and non-malignant hematologic disease. However, it is associated with high morbidity and mortality. A proportion of patients need intensive care due to infectious, immunological and/or toxic complications. The utility of intensive care unit (ICU) treatments as mechanical ventilation and renal replacement therapy for these patients is uncertain since mortality is high. We describe the most frequent complications and the treatment options concerning the ICU in recipients of allogeneic hematopoetic stem cells.
异基因造血干细胞移植可提高高危恶性和非恶性血液病患者的长期生存率。然而,它与高发病率和死亡率相关。一部分患者因感染、免疫和/或毒性并发症而需要重症监护。由于死亡率很高,重症监护病房(ICU)治疗如机械通气和肾脏替代疗法对这些患者的效用尚不确定。我们描述了异基因造血干细胞接受者中与ICU相关的最常见并发症及治疗选择。